Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ezutromid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTRN known ✓ | P46939 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.57 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ezutromid SCHEMBL29376738 | 1.00 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL30791155 | 1.00 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL31080435 | 1.00 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL3954452 | 0.92 | UTRN (0.84) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2245091 | 0.88 | UTRN (0.78) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2242906 | 0.88 | UTRN (0.78) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL3944431 | 0.87 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6PTPN2 | |
| SCHEMBL2245790 | 0.87 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2243039 | 0.87 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL4037442 | 0.87 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2026-05-14 | — | — | US | claimed |
| EP-4403171-A2 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | University of Maryland, Baltimore (US) | 2024-07-24 | — | — | EP | claimed |
| EP-3641741-B1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2024-03-20 | — | — | EP | claimed |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2023-08-03 | — | — | US | claimed |
| US-20200215035-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-07-09 | — | — | US | claimed |
| EP-3641741-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | University of Maryland, Baltimore (US) | 2020-04-29 | — | — | EP | claimed |
| EP-3500245-A1 | COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2019-06-26 | — | — | EP | claimed |
| WO-2018236879-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-12-27 | — | — | WO | claimed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | claimed |
| WO-2017168151-A1 | COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2017-10-05 | — | — | WO | claimed |
| EP-2170396-B1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2016-12-21 | — | — | EP | claimed |
| US-9492433-B2 | Pharmaceutical composition for the treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2016-11-15 | — | — | US | claimed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | claimed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | claimed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | claimed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | claimed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-2176246-A2 | POLYMORPHS OF A COMPOUND FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-21 | — | — | EP | claimed |
| US-20090048314-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | US | claimed |
| WO-2009021748-A2 | POLYMORPHS OF A COMPOUND FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | UTRN 11/4885CYP1A2 2784/4885AHR 4338/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | UTRN 11/4885CYP1A2 2784/4885AHR 4338/4885 |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBA1C, TUBB3, TUBB | UTRN 1579/4885CYP1A2 3166/4885AHR 4745/4885 |
| US-20090048314-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, MTPN | UTRN 1/4885CYP1A2 2660/4885AHR 4488/4885 |
| US-20200215035-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBA1C, TUBB3, TUBB | UTRN 1579/4885CYP1A2 3166/4885AHR 4745/4885 |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBB3, TUBB1, TUBB | UTRN 1572/4885CYP1A2 1852/4885AHR 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.